Verapamil Hydrochloride
Total Payments
$515,532
Transactions
7
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $440,690 | 5 | 0 |
| 2017 | $74,842 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $515,532 | 7 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| VERA-17022 | Mylan Pharmaceuticals Inc. | $291,197 | 0 |
| VERA-17023 | Mylan Pharmaceuticals Inc. | $224,335 | 0 |
Top Doctors Receiving Payments for Verapamil Hydrochloride
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Morgantown, WV | $515,532 | 7 |
Ad
Manufacturing Companies
- Mylan Pharmaceuticals Inc. $515,532
Product Information
- Type Drug
- Total Payments $515,532
- Total Doctors 0
- Transactions 7
About Verapamil Hydrochloride
Verapamil Hydrochloride is a drug associated with $515,532 in payments to 0 healthcare providers, recorded across 7 transactions in the CMS Open Payments database. The primary manufacturer is Mylan Pharmaceuticals Inc..
Payment data is available from 2017 to 2018. In 2018, $440,690 was paid across 5 transactions to 0 doctors.
The most common payment nature for Verapamil Hydrochloride is "Unspecified" ($515,532, 100.0% of total).
Verapamil Hydrochloride is associated with 2 research studies, including "VERA-17022" ($291,197).